Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)

Autor: Pierre Bordigoni, Danielle Canioni, Michèle Milili, Nathalie Lambert, Claire Galambrun, Marie Ouachée-Chardin, Filomeen Haerynck, Françoise Le Deist, Despina Moshous, Christelle Lenoir, Stephanie Rigaud, Lionel Galicier, Fabien Touzot, Capucine Picard, Mohamed Hamidou, Hirokazu Kanegane, Ester Mejstrikova, Helen Chapel, Eduardo López-Granados, Stéphane Blanche, Alain Dabadie, Jana Pachlopnik Schmid, Pierre-Simon Rohrlich, Fabian Hauck, Geneviève de Saint Basile, Claudin Schiff, Jean-Louis Stephan, Alain Fischer, Isabelle Pellier, Nizar Mahlaoui, Sylvain Latour, Alain Fourmaintraux, Vincent Barlogis

Publikováno v: Blood
Blood, American Society of Hematology, 2011, 117 (5), pp.1522-9. ⟨10.1182/blood-2010-07-298372⟩
Blood, 2011, 117 (5), pp.1522-9. ⟨10.1182/blood-2010-07-298372⟩
Blood; Vol 117
Blood, American Society of Hematology, 2011, 117 (5), pp.1522-9. 〈10.1182/blood-2010-07-298372〉

X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is cause

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe9d22dee92c4a2e0ddda891a9b2537
https://doi.org/10.1182/blood-2010-07-298372